ESPR
Esperion Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.18
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 418.2M | 403.1M | 332.3M | 116.3M | 75.5M |
| Cost of Revenue | 146.4M | 129.2M | 68.6M | 43.3M | 27.0M |
| Gross Profit | 271.9M | 273.9M | 263.7M | 73.1M | 48.5M |
| Operating Expenses | |||||
| R&D Expense | 44.3M | 47.9M | 46.2M | 86.1M | 118.9M |
| SG&A Expense | 165.9M | 165.8M | 163.1M | 142.5M | 109.1M |
| General & Admin Expense | — | — | 137.6M | — | — |
| Selling & Marketing Expense | — | — | 25.5M | — | — |
| Other Expenses | (14.1M) | — | — | — | — |
| Total Operating Expenses | 196.1M | 213.6M | 209.3M | 228.6M | 228.0M |
| Cost and Expenses | 342.5M | 342.9M | 277.9M | 271.9M | 255.0M |
| Operating Income (EBIT) | 75.8M | 60.3M | 54.4M | (155.6M) | (179.5M) |
| Non-Operating | |||||
| Interest Income | 1.1M | 3.5M | — | — | — |
| Interest Expense | 45.4M | 84.6M | 59.3M | 59.0M | 56.8M |
| Net Interest Income | (44.3M) | (81.1M) | (59.3M) | (59.0M) | (56.8M) |
| Other Non-Op Income/Expense | (81.4M) | (81.1M) | (106.1M) | (53.7M) | (54.2M) |
| Non-Operating Income (excl Interest) | 36.0M | (3.5M) | 46.9M | (5.3M) | (2.7M) |
| EBT (Pre-Tax Income) | (5.6M) | (20.8M) | (51.7M) | (209.2M) | (233.7M) |
| Income Tax Expense | 1.8M | 1.8M | — | — | — |
| Bottom Line | |||||
| Net Income | (7.4M) | (22.7M) | (51.7M) | (209.2M) | (233.7M) |
| Earnings from Cont. Ops | (7.4M) | (22.7M) | (51.7M) | (209.2M) | (233.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (7.4M) | (22.7M) | (51.7M) | (209.2M) | (233.7M) |
| Per Share | |||||
| Basic EPS | ($0.02) | ($0.11) | ($0.28) | ($2.03) | ($4.33) |
| Diluted EPS | ($0.06) | ($0.11) | ($0.28) | ($2.03) | ($4.33) |
| Revenue Per Share | $1.66 | $1.94 | $1.78 | $1.13 | $1.14 |
| Shares | |||||
| Basic Shares Outstanding | 251.4M | 207.9M | 187.2M | 103.1M | 66.4M |
| Diluted Shares Outstanding | 251.4M | 207.9M | 187.2M | 103.1M | 66.4M |
| Profitability Metrics | |||||
| EBITDA | 39.9M | 63.9M | 7.6M | (150.1M) | (176.3M) |
| D&A | 106.0K | 105.0K | 63.0K | 164.0K | 500.0K |
| EBIT | 39.8M | 63.8M | 7.5M | (150.3M) | (176.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026